Table 1.
Clinical-pathological features n (%)
| Cases | sTIL ≥ 50% | P value | pCR | P value | Overall Survival at 5 yr (OS = 50.1%) | P value | Progression free survival at 5 yr (DFS = 57.8%) | P value | |
| 435 | 181 | 48 | |||||||
| Age (yr), median (range) | 49 (24-84) | 49 (24-84) | 0.923 | 47 (28-80) | 0.472 | 0.512 | 0.833 | ||
| < 50 | 231 (53.1) | 96 (35.2) | 28 (12.1) | 48.8% | 59.7% | ||||
| ≥ 50 | 204 (46.9) | 85 (36.7) | 20 (9.8) | 51.7% | 55.9% | ||||
| Histological subtypes | 0.928 | 0.234 | 0.512 | 0.497 | |||||
| Ductal | 406 (93.3) | 169 (43.6) | 43 (10.6) | 49.0% | 57.5% | ||||
| Lobular | 21 (4.8) | 7 (36.8) | 2 (9.5) | 61.0% | 55.2% | ||||
| Others | 8 (1.8) | 5 (62.5) | 3 (37.5) | - | - | ||||
| Histological grade | < 0.001 | 0.170 | 0.001 | 0.006 | |||||
| G1-G2 | 200 (46.0) | 59 (32.6) | 17 (8.5) | 57.1% | 64.6% | ||||
| G3 | 227 (52.2) | 119 (65.7) | 29 (12.8) | 42.8% | 52.2% | ||||
| NR | 8 (1.8) | 3 (1.7) | 2 (25) | 83.3% | 45.7% | ||||
| ER | < 0.001 | 0.098 | < 0.001 | 0.000 | |||||
| No | 162 (37.2) | 89 (57.8) | 23 (14.2) | 36.1% | 47.1% | ||||
| Yes | 273 (62.8) | 92 (35.2) | 25 (9.2) | 58.2% | 64.3% | ||||
| PgR | 0.003 | 0.246 | < 0.001 | 0.000 | |||||
| No | 213 (49) | 104 (51.0) | 27 (12.7) | 41.0% | 50.0% | ||||
| Yes | 222 (51) | 77 (36.5) | 21 (9.5) | 58.4% | 64.8% | ||||
| HER2 | 0.002 | 0.135 | 0.334 | 0.135 | |||||
| No | 294 (67.6) | 106 (38.3) | 28 (9.5) | 53.7% | 60.4% | ||||
| Yes | 141 (32.4) | 75 (54.3) | 20 (14.2) | 40.8% | 52.3% | ||||
| Molecular subtypes | < 0.001 | 0.233 | < 0.001 | < 0.001 | |||||
| Luminal A | 107 (24.6) | 30 (29.7) | 13 (12) | 72.0% | 76.1% | ||||
| Luminal B | 165 (37.9) | 61 (38.4) | 12 (7) | 50.6% | 57.7% | ||||
| HER2-enriched | 77 (17.7) | 50 (66.7) | 10 (13) | 41.5% | 54.9% | ||||
| Triple-Negative | 86 (19.8) | 40 (50.0) | 13 (15) | 32.5% | 40.3% | ||||
| Tumor size (cm) | 0.183 | 0.019 | 0.490 | 0.250 | |||||
| Median (range) | 6.5 (1-24) | 6.5 (1-16) | 6.0 (2-15) | ||||||
| cT | |||||||||
| cT1-cT2 | 36 (8.3) | 19 (54.3) | 8 (22.2) | 55.0% | 69.2% | ||||
| cT3-cT4 | 399 (91.7) | 162 (42.6) | 40 (10) | 49.6% | 56.8% | ||||
| cN | 0.084 | 0.743 | 0.007 | 0.001 | |||||
| cN0 | 83 (19.1) | 28 (35.0) | 10 (12) | 65.8% | 77.0% | ||||
| cN1-cN2-cN3 | 352 (80.9) | 153 (45.7) | 38 (10.8) | 47.2% | 54.2% | ||||
| Clinical stage | 0.192 | 0.088 | 0.155 | 0.004 | |||||
| II | 72 (16.6) | 26 (36.6) | 12 (16.7) | 62.1% | 74.3% | ||||
| III | 363 (83.4) | 155 (45.1) | 36 (9.9) | 48.1% | 55.4% | ||||
| sTIL% | 0.002 | 0.598 | 0.747 | ||||||
| Median (range) | 40 (2-95) | 70 (60-95) | 65 (5-95) | ||||||
| < 50% | 266 (61.1) | 0 (0) | 20 (7.5) | 49.6% | 55.7% | ||||
| ≥ 50% | 149 (34.3) | 181 (100) | 26 (17.4) | 53.9% | 63.1% | ||||
| Missing data | 20 (4.6) | 20 (0) | 2 (10) | - | - | ||||
| TLCS (d) | 0.411 | 0.633 | 0.317 | 0.156 | |||||
| Median (range) | 63 (5-982) | 58 (8-982) | 65 (8-281) | ||||||
| Shorter than median | 207 (47.6) | 91 (45.5) | 22 (10.6) | 48.5% | 55.0% | ||||
| Longer than median | 211 (48.5) | 82 (41.4) | 26 (12.3) | 56.7% | 61.2% | ||||
| Missing data | 17 (3.9) | 8 (47.1) | 0 (0) | 17.6% | 46.3% | ||||
| pCR | 0.029 | 0.002 | 0.002 | ||||||
| No | 387 (89) | 154 (41.7) | 0 (0) | 47.4% | 55.1% | ||||
| Yes | 48 (11) | 27 (58.7) | 48 (100) | 85.1% | 84.9% | ||||
| Relapse | 0.895 | < 0.001 | < 0.001 | ||||||
| No | 284 (65.3) | 118 (43.4) | 42 (14.8) | 81.6% | - | ||||
| Yes | 151 (34.7) | 63 (44.1) | 6 (4) | 8.58% | - |
TIL: Tumor-infiltrating lymphocytes; pCR: Pathological complete response; OS: Overall survival; DFS: Disease free survival; PgR: Progesterone; TLCS: Time-From-Last-Chemotherapy-To-Surgery.